

Program of the 4th RUCTRIMS CONGRESS 23-25 of September 2021
September 23

	Hall 2
09:00-10:00	Neurological quest – from diagnosis and types of course to prognosis and selection of therapy – clinical cases. <i>Chair – Boyko AN, cases presented by Omarova VF, Sivetseva SA, Kasatkin DS</i>
10:00-10:10	<i>Break</i>
	Hall 1
10:10-11:10	<i>Symposium Sanofi</i> «8 infusions to freedom» <i>Chair: Boyko AN</i> Popova EV – At decade border: longitudinal results of TIR – 20 min Bachtiarova KZ – Expert view on selection of monoclonal antibodies in MS – 20 min Sivertseva SA – Best practice to treat MS patients: World and Russian experience – 20 min
11:10-11:20	<i>Break</i>
	Hall 2
11:20-12:20	<i>Symposium – Novartis</i> «Time dictates: Kayendra - targeted therapy for SPMS» <i>Chairs: Boyko AN, Sivertseva SA, Popova EV</i> Boyko AN - Opening the horizons of therapy for SPMS - 20 min Sivertseva SA- Targeted therapy of SPMS: reduction of exacerbations, slowing of progression and neurodegenerative changes-20 min Popova EV - Kayendra for patients with SPMS - 20 min
12:20-12:30	<i>Break</i>
	Hall 1
12:30-13:30	MS School: Individual selection of therapy of MS <i>Chairs: Zacharova MN, Popova EV, Spirin NN</i> Cases reported by Omarova MA, Sviridova AA, Dubchenko EA
13:30-14:00	<i>Break</i>
	Hall 3
13:30-14:00	Masterclass: MS as a diagnosis of exclusion– Boyko AN
	Hall 1
14:00-15:00	MS School: MRI in cases of demyelinating diseases <i>Chairs: Totolyan NA, Bruchov VV</i> Speakers: Bruchov VV, Belov CA
15:00-15:30	<i>Break</i>
	Hall 2
15:30-16:30	<i>Symposium Rosch</i> «NMOSD: state of the art» <i>Chair: Boyko AN</i> Krasnov VS - Neuromyelitis optica spectrum disorder - portrait of the patient - 15 min

	<p>Simaniv TO - Epidemiology and diagnosis of NMOSD – 15 min Boyko AN - Pathogenesis of NMOSD and the role of IL-6 in the development of the disease – 15 min Traboulee A - Suppression of the IL-6 pathway as a therapeutic strategy in NMOSD (online) – 15 min</p>
	Hall 1
16:30-18:00	<p><u>Symposium 1. Greek -Russian symposium on neuroimmunology</u> <i>Chair: Boyko AN</i> Grigoriadis N (Greece) - Cell therapy in MS and neuroimmunology – 15 min (video) <u>Melnikov MV</u>, Sviridova AA, Solodova TV, Paschenkov MV, Boyko AN (Moscow) - Biogenic amine receptors as a therapeutic target in multiple sclerosis - 15 min Boziki M (Greece) - Biomarkers in Multiple Sclerosis – 15 min (video) Bakirtzis C (Greece) – Cognition in MS: Current treatment strategies and the role of DMTs - 15 min (video) <u>Totolyan NA</u>, Krasnov VS, Kushnir YB. - Pathological synthesis of immunoglobulins in MS and other neurological diseases. - 15 min Bisaga GN - The place and prospects of hematopoietic stem cell transplantation in the treatment of multiple sclerosis. Overview of global trends and own data – 15 min</p>
	Hall 3
18:00-18:30	<p><i>Round table (supported by Merck)</i> Actual issues of MS care in the new realities. Discussion of international experience <i>Chair: Boyko AN, participants - neurologists from Kazakhstan, Belarus and other countries</i></p>
19:00	<i>Sightseeing tour</i>

September 24

	Hall 1
09:00-10:00	<i>Symposium– J&J- Janssen</i> «Plegridy – 2 years in Practical use in Government Program HCD: the experience and new perspectives» <i>Chair: Boyko AN</i> Boyko AN - Evolution of approaches to interferon therapy. Focus on patient convenience Sivertseva SA - Clinical studies and accumulated experience in Plegridi therapy Popova EV - Local experience of Plegridi therapy in real clinical practice. Clinical cases
10:00-10:30	<i>Break</i>
	Hall 1
10:30-12:40	Opening and Plenary Session <i>Chairs: Boyko AN , Belova AN, Zakharova MN, Spirin NN</i> Fernandez O (Spain) - Organization of MS care in Europe (from EAN and ECF) – 20 min (video). Derfuss T (Switzerland) - Oral treatments for Multiple Sclerosis – 20 min (video). Gouider R (Tunis) - MS epidemiology with special attention to populations with previously low MS risk (WFN) - 20 min (video) Boyko AN – Current epidemiology of MS – 20 min Belova AN – MS in Nizhny Novgorod region - 10 min Zakharova MN – Current approaches to MS therapy - 20 min Khachanova NV – Practical use of clinical recommendations of MS diagnosis and therapy – 20 min (<i>supported by Bristol Myers Squibb and Generium</i>)
12:40-13:00	<i>Break</i>
13:00-14:00	<i>Symposium J&J-Janssen</i> «Modern and timely therapy of HAMS» <i>Chairs: Kasatkin D. S., Khachanova N. V., Yakushina T. I.</i> Kasatkin DS - Evolution of approaches to the treatment of PITRS. Focus on early and long-term effectiveness Khachanova NV - Evolution of views on the choice of high-performance therapy from the point of view of safety: what has changed in 15 years? Yakushina TI - Local experience of Tizabri therapy in real clinical practice. Clinical cases
14:00-14:30	<i>Break</i>
	Hall 3
14:00-14:30	Master-class: Optimization of MS therapy –Khachanova NV
	Hall 1
14:30-16:05	<u>Symposium 2. Atypical forms of demyelinating diseases, differential diagnosis</u> <i>Chairs: Volkova LI, Smagina IV</i> Giovannoni G (Great Britain) - Pitfalls in MS differential diagnosis - 20 min (video) Volkova LI - Creutzfeldt-Jakob disease (clinical observations) - 15 min Sherman MA - Guillain-Barre syndrome (current state of the issue) - 15 min

	<p>Topuzova MP - The complexity of the differential diagnosis of autoimmune myelitis. - 15 min</p> <p>Smagina IV - Clinical case of atypical demyelination– 15 min</p> <p>Prakhova LN - Difficulties in diagnosing combined demyelinating and vascular lesions of the central nervous system - 15 min</p>
	Hall 2
14:30-16:05	<p><u>Symposium 3. Age, gender and ethnic peculiarities of autoimmune diseases of CNS</u></p> <p><i>Chairs: Bykova OV, Spirin NN</i></p> <p>Ghezzi A (Italy) - Pediatric MS differential diagnosis and therapies - 20 min (video)</p> <p>Houtchen M (USA) – Pregnancies and family planning in MS – 15 min (видео)</p> <p>Bykova OV - Acute disseminated demyelination in children-evolution of ideas about diagnosis and therapy-15 min</p> <p><u>Spirin NN</u>, Spirina NN, Kiseleva EV, Shipova EG - Aggressive multiple sclerosis. Is forecasting possible? -15 min</p> <p>Popova EV - Features of the course of MS against the background of COVID-19-15 min</p>
16:05-16:15	<i>Break</i>
	Hall 1
16:15-17:55	<p><u>Symposium 4. MS registers, current and future (together with MS Alliance)</u></p> <p><i>Chairs Bakhtiyarova KZ, Sivertseva SA</i></p> <p>Peeters L. (Belguim) –MS Data Alliance: a global multi-stakeholder collaboration to scale-up real-world health data research- 20 min (video)</p> <p>Bakhtiyarova KZ - Epidemiology of multiple sclerosis in the Republic of Bashkortostan at the present stage-15 min</p> <p>Petrov SV - Experience in creating regional registers of RS – 15 min</p> <p><u>Kochergin IA</u>, Abramova AA, Zakharova MN - MS registers and assessment of the timeliness of diagnosis and initiation of MS therapy-15 min</p> <p>Sivertseva SA - Features of the work of the MS Center in the conditions of the Covid-19 pandemic-15 min</p> <p>Presentations of regional MS Centers – 20 min</p>
	Hall 2
16:15-17:55	<p><u>Symposium 5. NMOSD and other syndromes, associated with antibodies to AQP-4 and MOG (together with ParadigMS)</u></p> <p><i>Chairs: Totolyan NA, Zakharova MN</i></p> <p>Balashov K (USA) - Specificity of neuroimaging in MS – 20 min (video)</p> <p>Siva A (Turkey) - MS/NMOSD/MOGAD overlap syndromes and beyond - 20 min (online)</p> <p><u>Simaniv TO</u>, Eliseeva DD, Askarova LSH, Zakharova MN.- Spectrum of opticoneuromyelitis diseases: approaches to diagnosis and treatment – 15 min</p> <p><u>Krasnov VS</u>, Totolyan NA, Moshnikova AN, Nazarov VD - Difficulties of clinical and laboratory diagnostics and practical aspects of therapy of opticoneuromyelitis spectrum diseases-15 min</p> <p><u>Spirin NN</u>, Kiseleva EV, Shipova EG - Antibodies to MOG and MOG-associated syndromes-15 min</p> <p>Bryukhov BB - MRI in NMOSD – 15 min</p>
18:00-19:00	Poster session
20:00	Social event

September 25

	Hall 2
09:00-10:00	<p><i>Symposium Roche</i> «How to slow down the progression of MS: The experience of using ocrelizumab in clinical practice» <i>Chairs: Khachanova NV, Schmidt TE.</i> Discussion panel Kasatkin DS, Abroskina MV, Bakhtiyarova KZ, Sokolova AA. Analysis of clinical cases</p>
10:00-10:10	<i>Break</i>
	Hall 1
10:10-11:40	<p><u>Symposium of the European Charcot Foundation “Understanding the progressive phase of the disease”</u> <i>Chairs: Boyko AN, Comi G</i> Hartung HP (Germany) - Pathophysiology of progression in MS- - 20 min (online) Soelberg Sørensen P (Denmark) - Understanding the progressive phase of the disease. Epidemiological studies – 15 min (video) Trojano M (Italy) - Role of observational studies – 15 min (video) Montalban X (Canada, Spain) - How to treat progressive MS in practice - 20 min (video) Comi G (Italy) - Future treatments in progressive MS –20 min (online)</p>
11:40-12:10	<i>Break</i>
	Hall 3
11:40-12:10	<p>Master class Guseva ME-Art therapy</p>
	Hall 1
12:10-13:10	<p><i>Symposium Merck</i> «The revolution in the treatment of highly active MS (HAMS): new opportunities» <i>Chairs: Boyko AN, Khabirov FA, Totolyan NA.</i> Boyko AN - Transformation of approaches to the treatment of HAMS, Russian experience - 20 min Kasatkin DS - Start, continuation and further tactics of HAMS therapy in a pandemic - 20 min Popova EV - Features of family planning in patients with MS, choice of therapy-20 min</p>
	Hall 2
13:10-13:40	<p><i>Symposium J&J - Janssen</i> «MS therapy in the period of global infectious threats» <i>Speakers: Khachanova NV, Harit SM</i></p>
13:40-13:50	<i>Break</i>
	Hall 1
13:50-15:10	<p><u>Symposium 6. Neurodegeneration-the beginning or consequence of autoimmune inflammation</u> <i>Chairs: Stolyarov ID, Spirin NN</i> Hartung HP (Germany) - The role of the innate immune system in MS - 20 min (video) Abdurasulova IN - The role of the gut microbiota in multiple sclerosis. Prospects of treatment with probiotics - 15 min Favorova OO - MicroRNAs and their participation in the pathogenesis of MS - 15 min</p>

	<p>Predtechenskaya EV, Rogachev AD, Kasakin MF, Koval BB, Pokrovsky AH (Novosibirsk) - Metabolomic screening of markers of neurodegeneration in MS (Novosibirsk) - 15 min Stolyarov ID (St. Petersburg) - The brain of a patient with MS – 15 min</p>
	Hall 2
13:50-15:10	<p><u>Symposium 7. The role of the patient and their relatives in assessing the effectiveness of therapy (in collaboration with RMSS, MS in 21Century and MSPRO)</u> <i>Chairs: Vlasov YV, Guseva ME</i> Vlasov YV - The influence of civil and expert communities on the issues of providing medical care to patients with MS – 20 min Boyko AN - The role of the family in the treatment selection and control of MS - 15 min Matvievskaya OV - Life with MS, the patient's view - 15 min Petrov AM - Safety aspects of MS therapy - 15 min Guseva ME – New facilities of the art therapy in MS – 15 min</p>
15:10-15:20	<i>Break</i>
	Hall 1
15:20-16:35	<p><u>Symposium 8. New methods of MS therapy</u> <i>Chairs: Sivertseva SA, Khabirov FA</i> Kappos L - Possible future on monoclonal antibodies in MS therapy– 20 min (video) Selmaj K - Safety of anti-B-cells therapies– 20 мин (video) Kesselring J - The Rehabilitation in Neurorestoration in MS– 20 мин (video) Sivertseva SA - Program low-intensity rehabilitation of patients with MS - 15 min</p>
	Hall 2
15:20-16:35	<p><u>Symposium 9. New biomarkers in MS diagnosis and treatment control</u> <i>Chairs: Alifirova VM, Schmidt TE</i> Pelletier D – MS-specific atrophy – 20 min (video) Stankoff B - PET imaging of the mechanisms driving disability in Multiple Sclerosis – 20 min (video) Kulakova OG - The effect of the interaction of mitochondrial and nuclear genomes on the risk of developing MS -15 min</p>
16:35-16:40	<i>Break</i>
	Hall 2
16:40-17:40	<p><i>Symposium – Biocad</i> «Multiple sclerosis under control: a wide range of DMTs. Innovative treatment methods» <i>Chairs: Popova EV, Boyko AN, Melnikov MV</i> Popova EV- Multiple sclerosis and comorbid pathologies: risk assessment. Selection of DMTs, taking into account somatic status – 20 min Boyko AN – Patient reported outcomes (PRO) in the daily practice of the doctor - 20 min Melnikov MV - Effect of glatiramer acetate on the Th17-induced dendritic cell immune response in multiple sclerosis. Applicability of the results in clinical practice – 20 min</p>
	Hall 1
17:40-18:40	<p><i>Symposium– Novartis</i> «Evolution of the paradigm of MS treatment» <i>Chair: Spirin NN</i></p>

	Khachanova NV– From pathophysiology and clinical trials to selection of DMTs – 20 min Boyko AN– ANTI-B-cell therapy as longtime strategy in MS therapy – 20 min Popova EV – From early start with high effective DMTS to longitudinal control of MS – 20 min
	Hall 3
18:10-18:40	Working Group on MS registers <i>Chairs: Boyko AN, Peeters L</i>
18:40-19:00	<i>Break</i>
	Hall 1
19:30-20:00	Congress closing, RUCTRIMS meeting